HTHQ (Synonyms: 1-O-hexyl-2,3,5-trimethylhydroquinone; HX-1171; BTT-105)

Name: HTHQ
Brand: MedChemExpress
SKU: HY-100768
Rating: 5.0 (3 reviews)

Cat. No.: HY-100768 Purity: 99.89%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone) is a potent lipophilic phenolic antioxidant. HTHQ has considerable anti-oxidative activity by directly reacting with reactive oxygen species (ROS) and scavenging ROS to form more stable free radicals.

For research use only. We do not sell to patients.

HTHQ Chemical Structure

CAS No. : 148081-72-5

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 49	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 49	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 45	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 69	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 96	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 132	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

2 Publications Citing Use of MCE HTHQ

: HTHQ purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Sep;24(18):10468-10477. [Abstract]; HTHQ against cerebral I/R injury via Nrf2 antioxidant pathway. Western blots showing the level of Nrf2, HO-1, nuclear Nrf2 and cytosolic Nrf2 in mice following cerebral I/R. The expression of Nrf2, HO-1 and nuclear Nrf2 is also significantly increased after HTHQ treatment.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

ROS^[1]

In Vitro

HTHQ (0-100 μM; 24 hours; PC12 cells) treatment increases cell viabilities in a dose-dependent manner^[1].
HTHQ (10 μM; 0.6-24 hours; PC12 cells) inhibits 3,4-L-Dihydroxyphenylalanine (L-DOPA) -induced phosphorylation of sustaines extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). HTHQ also normalizes L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression, promoting cell survival^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	PC12 cells
Concentration:	0 μM, 1 μM, 10 μM, and 100 μM
Incubation Time:	24 hours
Result:	Reduced cell viability at 24 hours caused by both 100 and 200 µM L-DOPA was significantly attenuated.

Western Blot Analysis^[1]

Cell Line:	PC12 cells
Concentration:	10 μM
Incubation Time:	0.6-24 hours
Result:	Inhibited L-DOPA-induced phosphorylation of sustained extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). And also normalized L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression.

In Vivo

HTHQ (50-200 mg/kg; oral administration; for 4 weeks; specific pathogen-free male Sprague Dawley rats) treatment significantly improves liver weight and serum chemistry level. HTHQ reduces hydroxyproline and malondialdehyde level in the liver. HTHQ treatment also reduces fibrotic septa. HTHQ administration shows reduced mRNA level of PDGF (Plateletderived growth factor) , α-SMA (α-smooth muscle actin) and TGF-β (transforming growth factor-β) than DMN-induced hepetic fibrosis animals in the liver tissue^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN) ^[2]
Dosage:	50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:	Oral administration; for 4 weeks
Result:	Improved against DMN-induced liver fibrosis in male SD rats.

Clinical Trial

Molecular Weight

236.35

Formula

C₁₅H₂₄O₂

CAS No.

148081-72-5

Appearance

Solid

Color

White to off-white

SMILES

OC1=C(C)C=C(OCCCCCC)C(C)=C1C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (423.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.2310 mL	21.1551 mL	42.3101 mL
5 mM	0.8462 mL	4.2310 mL	8.4620 mL
10 mM	0.4231 mL	2.1155 mL	4.2310 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 25 mg/mL (105.78 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (250.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.89%

Select Batch:

Data Sheet (275 KB) SDS (394 KB)

COA (242 KB) HNMR (187 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Park HJ, et al. 1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells. Molecules. 2019 Mar 1;24(5). pii: E867. [Content Brief]

[2]. Jung YR et al. Inhibitory Effect of 1-O-Hexyl-2,3,5-Trimethylhydroquinone on Dimethylnitrosamine-induced Liver Fibrosis in Male SD Rats. Toxicol Res. 2010 Sep;26(3):193-201. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.2310 mL	21.1551 mL	42.3101 mL	105.7753 mL
	5 mM	0.8462 mL	4.2310 mL	8.4620 mL	21.1551 mL
	10 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	15 mM	0.2821 mL	1.4103 mL	2.8207 mL	7.0517 mL
	20 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	25 mM	0.1692 mL	0.8462 mL	1.6924 mL	4.2310 mL
	30 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	40 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	50 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	60 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	80 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	100 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL

HTHQ Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HTHQ148081-72-51-O-hexyl-2,3,5-trimethylhydroquinone HX-1171 BTT-105HX1171HX 1171HX-1171BTT105BTT 105BTT-105Reactive Oxygen SpeciesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

HTHQ (Synonyms: 1-O-hexyl-2,3,5-trimethylhydroquinone; HX-1171; BTT-105)

Customer Review

HTHQ Related Antibodies

2 Publications Citing Use of MCE HTHQ

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

HTHQ Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

HTHQ Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report